These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36016173)

  • 41. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
    Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
    BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inactivated influenza virus vaccines: the future of TIV and QIV.
    Schotsaert M; García-Sastre A
    Curr Opin Virol; 2017 Apr; 23():102-106. PubMed ID: 28505524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
    Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Effectiveness of Vaccination of Older Adults with an MF59
    Jacob J; Biering-Sørensen T; Holger Ehlers L; Edwards CH; Mohn KG; Nilsson A; Hjelmgren J; Ma W; Sharma Y; Ciglia E; Mould-Quevedo J
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Redondo E; Drago G; López-Belmonte JL; Guillén JM; Bricout H; Alvarez FP; Callejo D; Gil de Miguel Á
    Vaccine; 2021 Aug; 39(36):5138-5145. PubMed ID: 34344553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
    Huang C; Fu X; Zhou Y; Mi F; Tian G; Liu X; Wu J; Ding C; Yan D; Li L; Yang S
    Vaccine; 2020 Feb; 38(6):1332-1344. PubMed ID: 31948819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal.
    Alvarez FP; Chevalier P; Borms M; Bricout H; Marques C; Soininen A; Sainio T; Petit C; de Courville C
    J Med Econ; 2023; 26(1):710-719. PubMed ID: 36960689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.
    Langley JM; Carmona Martinez A; Chatterjee A; Halperin SA; McNeil S; Reisinger KS; Aggarwal N; Huang LM; Peng CT; Garcia-Sicilia J; Salamanca de la Cueva I; Cabañas F; Treviño-Garza C; Rodríguez-Weber MA; de la O M; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    J Infect Dis; 2013 Aug; 208(4):544-53. PubMed ID: 23847058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea.
    Song Y; Shim E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2348124. PubMed ID: 38714332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quadrivalent versus trivalent influenza vaccine: clinical outcomes in two influenza seasons, historical cohort study.
    Shasha D; Valinsky L; Hershkowitz Sikron F; Glatman-Freedman A; Mandelboim M; Toledano A; Paran Y; Ben-Ami R; Goldman D
    Clin Microbiol Infect; 2020 Jan; 26(1):101-106. PubMed ID: 31108229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis.
    Liang Y; Jing-Xia G; Ma L; Ni L; Chaolie R; Zhou J; Guo-Yang L
    Hum Vaccin Immunother; 2021 Oct; 17(10):3652-3661. PubMed ID: 34156322
    [No Abstract]   [Full Text] [Related]  

  • 54. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 55. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
    Greenberg DP; Robertson CA; Landolfi VA; Bhaumik A; Senders SD; Decker MD
    Pediatr Infect Dis J; 2014 Jun; 33(6):630-6. PubMed ID: 24445833
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.
    Kohli MA; Maschio M; Mould-Quevedo JF; Drummond M; Weinstein MC
    Hum Vaccin Immunother; 2021 Nov; 17(11):4603-4610. PubMed ID: 34550848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18-64 years: A systematic review and Meta-analysis].
    Meng ZY; Zhang JY; Zhang ZG; Luo D; Yang XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec; 39(12):1636-1641. PubMed ID: 30572392
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.
    Hu Y; Shao M; Hu Y; Liang Q; Jia N; Chu K; Xu L; Li J; Li C; Zhu F
    Hum Vaccin Immunother; 2020 Jul; 16(7):1691-1698. PubMed ID: 32347785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study.
    Milne GJ; Halder N; Kelso JK; Barr IG; Moyes J; Kahn K; Twine R; Cohen C
    Influenza Other Respir Viruses; 2016 Jul; 10(4):324-32. PubMed ID: 26663701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France.
    Paccalin M; Gavazzi G; Berkovitch Q; Leleu H; Moreau R; Ciglia E; Burlet N; Mould-Quevedo JF
    Vaccines (Basel); 2024 May; 12(6):. PubMed ID: 38932304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.